Dose-Finding Study of Favipiravir in the Treatment of Uncomplicated Influenza

You may be eligible if

• 1. Patients who test positive for influenza A or B by a commercially available Rapid Antigen Test (RAT) of the nasopharynx. A patient with a negative RAT result may still enroll if the sponsor and investigator agree that there is a known influenza outbreak circulating in the community.
• 2. Patients ≥ 20 but \< 65 years of age with a temperature (oral) of 100.4°F (38.0°C) or more; patients ≥ 65 years of age with a temperature (oral) of 100.0°F (37.8°C) or more at the first visit, or in the 6 hours prior if antipyretics were taken.
• 3. Patients with 2 or more of the following symptoms (moderate to severe in intensity) at the time of enrollment:
• * Cough
• * Sore throat
• * Headache
• * Nasal congestion
• * Feeling feverish
• * Body aches and pains
• * Fatigue (tiredness)
• 2. Patients who have underlying chronic respiratory disease (e.g., chronic obstructive pulmonary disease \[COPD\], chronic bronchitis, diffuse panbronchiolitis, bronchiectasis, pulmonary emphysema, pulmonary fibrosis, bronchial asthma, or old tuberculosis).
• 3. Patients who at the beginning of the study are suspected of having bacterial respiratory infection (i.e., expectoration of purulent or mucopurulent sputum and/or infiltrate in lung in a chest x-ray, etc.).
• 4. Patients who have serious chronic diseases. For example, patients with HIV, cancer (i.e., requiring chemotherapy within the preceding 6 months), cirrhosis (end-stage), and/or unstable renal, cardiac, pulmonary, neurologic, vascular, or endocrinologic disease states requiring medication dose adjustments within the last 30 days.